Page 108 - NobleCon21

Health Care
Date November 20, 2025 Health Care
52wk High $12.90
52wk Low $2.14 Kalaris Therapeutics, Inc. KLRS $7.07
628 Middlefield Road
Palo Alto, CA 94301

(USD - in millions) kalaristx.com
Market Cap 124.9
Enterprise 49.5
Basic Shares Out. 18.70 COMPANY OVERVIEW
Float 4.63
Institutional Holdings 9.50% Detailed Analysis:Channelchek.com
Short Interest 0.40
Avg. 90-Day Volume 0.35 Founded by experienced leaders in ophthalmology drug development
and commercialization, Kalaris is a clinical-stage biopharmaceutical
company dedicated to the development and commercialization of
treatments for prevalent retinal diseases.
EPS Data
2022 2023 2024
CQ1 N/A N/A N/A
CQ2 N/A N/A N/A

CQ3 N/A N/A N/A
CQ4 N/A N/A N/A
CY N/A N/A N/A Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 2.24
ROE (ttm) NM
Debt-to-Total Cap. (mrq) 3.56
Fiscal Year End 31-Dec
628 Middlefield Palo Alto CA 94301

Key Executives
CEO: Oxtoby, Andrew
CFO: Gall, Matthew
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures